Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its participation in two upcoming investor conferences.

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced its participation in two upcoming investor conferences. Management will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:30 p.m. ET, and at the Evercore ISI HealthCONx Conference on December 1 at 2:40 PM ET. Live webcasts and archived recordings will be accessible on Avadel’s Investor Relations website for 90 days post-conference. Avadel focuses on innovative treatments like LUMRYZ™, aimed at addressing narcolepsy symptoms.

Argus Session date unavailable

-2.92% session move Open Argus

Details

News Market Reaction – AVDL

The recorded move for AVDL in the trading session of this news was -2.92%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Ireland, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

• Piper Sandler 34^th Annual Healthcare Conference: Fireside chat on Tuesday, November 29 at 3:30 p.m. ET.
• Evercore ISI HealthCONx Conference: Fireside chat on Thursday, December 1 at 2:40 PM ET.

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Avadel Pharmaceuticals participating in investor conferences?

Avadel Pharmaceuticals will participate in the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:30 p.m. ET and the Evercore ISI HealthCONx Conference on December 1 at 2:40 PM ET.

Where can I watch the Avadel Pharmaceuticals investor conference webcasts?

The live webcasts and archived recordings of the investor conferences can be accessed on Avadel’s Investor Relations website for 90 days following each event.

What is the focus of Avadel Pharmaceuticals?

Avadel Pharmaceuticals focuses on transforming medicines to improve patients' lives, particularly through innovative treatments like LUMRYZ™ for narcolepsy.

What is LUMRYZ™ by Avadel Pharmaceuticals?

LUMRYZ™ is an investigational formulation of sodium oxybate designed for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy.